SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Safety and effectiveness of Co-careldopa for motor recovery in post-stroke patients: A Systematic Review.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStroke remains a major global contributor to long-term disability, with motor impairments being among the most debilitating outcomes. Co-careldopa, a combination of levodopa and carbidopa, has been proposed as an adjunct to physiotherapy to enhance motor recovery. However, its clinical efficacy and safety profile are still under investigation. This systematic review evaluates the therapeutic potential and tolerability of co-careldopa in post-stroke motor rehabilitation.
methodsA comprehensive literature search was conducted across PubMed, Google Scholar and Cochrane Library, up to July 2024. Randomized controlled trials and clinical trials comparing co-careldopa to placebo in post-stroke patients were included. Data extraction and screening were performed independently by two reviewers, and methodological quality was assessed using the Cochrane RoB 2.0 tool.
resultsFollow-up periods across studies ranged from 5 weeks to 12 months. Short-term motor improvements were observed, along with reporting significant gains in Rivermead Motor Assessment scores, and another study noting a 79.1% improvement in motor indices among cortical stroke patients versus 49% in controls. However, the largest multicenter trial, found no significant long-term benefit in walking ability. Psychological outcomes showed modest improvements in mood and caregiver burden, while cognitive function remained largely unaffected. Adverse events were infrequent and mild, including nausea and muscle stiffness, with few serious drug-related incidents.
conclusionCo-careldopa may support motor recovery in early stroke phases and is generally well-tolerated. Nonetheless, further robust trials are needed to confirm its long-term efficacy and broader clinical utility.
Indexed as
Identifiers
41108485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.